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Background: The emergence of coronavirus disease 2019 (COVID-19) pandemic has crippled the healthcare
systems all over the world. Cancer treatment is indispensable and disruption in its provision can lead to unan
ticipated consequences. No local data exists that has quantified the impact of COVID-19 pandemic on breast
cancer surgery in a lower middle-income country (LMIC), therefore, the present retrospective comparative cohort
study is directed to determine the trends in breast surgery operative volumes and its outcomes at our institution
in Pakistan.
Materials and methods: Data was collected retrospectively from Pre-COVID-19 and COVID-19 era to determine
impact of the current pandemic on breast cancer management practices and outcomes.
Results: Cohort results showed a decline in the number of surgeries during COVID-19 era. A total 149 cases were
operated during study period vs. 231 during same Pre-COVID-19 i.e. a 35.5% drop in cancer surgeries. In early
COVID-19 time frame, only 4 patients had breast reconstruction, 12 out of 149 (8.05%) surgical candidates were
identified having positive COVID-19 status preoperatively and one ASA class 3 patient caught COVID-19 postsurgery and succumbed to virus.
Conclusion: Pandemic has a negative effect on cancer management in a LMIC with compromised access and care
of cancer patients.

1. Introduction
The intractable outbreak of coronavirus disease 2019 (COVID-19)
pandemic has made drastic changes in the world of work. Besides a
continuous threat to public health, the economic and social de
rangements threatens the long term subsistence and well-being of mil
lions of people. The beta coronavirus or severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), the infecting pathogen
accountable for this fatal ongoing pandemic, had made its first attack in
Wuhan, China on 17th November 2019 [1,2]. Since then, it has spread
globally claiming 4,666,334 lives and infecting 226,844,344 individuals
from all across the globe by 17 September 2021 [3]. The outbreak of
COVID-19 has been running a course of rise and fall with new variants
and up till now, the world has faced four spells of this contagion with
each spell being more severe in intensity and causing more causalities
from the preceding one [4].

Pakistan a lower-middle-income nation has a restricted amount of
budget to spend on healthcare and coupled with a finite supply of re
sources is constantly grappling with the third wave of COVID-19 by
taking unprecedented measures to counter the deleterious re
verberations of its crisis and to prevent itself from being caught in a
dreadful situation faced by its neighboring countries like India and Iran
[5,6]. As per the government’s official portal, Pakistan has recorded 1,
223,841 cases and 27,206 deaths due to COVID-19 by 19 September
2021. Therefore, the government has imported substantial doses of
various vaccines effective against COVID-19 in order to curb the perilous
spread of this contagion and successfully administered 72,986,511 doses
of it in a population of over 212 million people [7].
Since the outset of this disease, the healthcare organizations all over
the world have incorporated necessary changes in their system to pro
vide unprejudiced essential health services to every patient and partic
ularly to those battling cancer amidst the current unfurling health crises
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as data has clearly underscored the fact that cancer patients can easily
become victims of SARS-CoV-2 virus infection and are more prone to
develop serious complications as compared to general population [8,9].
As a result, American Society of Breast Surgeons (ASBrS), the National
Accreditation Program for Breast Centers (NAPBC), the National
Comprehensive Care Network (NCCN), European Society for Medical
Oncology (ESMO) and other oncology institutions devised a structured
framework on the management approach of breast cancer cases in par
allel to conserving resources for utilizing them in the ensuing public
health crises spawned by COVID-19 [10,11]. In our previously published
work, we concluded that timely implementation of these health policies
and multidisciplinary participation in our institution maintained infec
tivity and fatality at a lowest possible rate among breast cancer cases
despite of high constraints to health resources [12].
However, not enough research has explored the change in the breast
surgery operative volume brought on by the rapidly evolving nature of
the ongoing pandemic. Hence, we conducted a study to assess the con
sequences of COVID-19 outbreak on the surgical management of breast
cancer patients in our institution by comparing the volume of breast
surgeries performed and its outcomes before the global pandemic era
versus those operated during the unravelling pandemic. We hope that
this study will be a contribution from a developing country to the
management policies of breast surgery clinical practice and will add to
the body of literature.

Demographic, clinicopathological and treatment characteristics data
of all the study participants was extracted from the institutional medical
records using a data collection proforma designed specifically for this
research. Following parameters of the study population were included in
the analysis: age at diagnosis, comorbidities, tumour pathology, tumour
grade, stage and molecular subtype of breast carcinoma, institution of
neoadjuvant chemotherapy/hormonal therapy, waiting time for sur
gery, type of surgical procedure performed, pre-operative COVID-19 RTPCR test done or not, its result, length of post-operative hospital stay,
occurrence of any COVID-19 symptoms post-operatively during hospital
stay or within one week after discharge or development of any
complication after surgery, waiting time for postoperative oncological
consultation and commencement of adjuvant chemotherapy or
radiotherapy.
Waiting time for surgery was enumerated as number of days from
initial histological diagnosis of cancer to the date of surgery for patients
who were advised upfront surgery. For patients who received neo
adjuvant chemotherapy it was calculated as the number of days from the
last chemotherapy cycle administration to the date of surgery per
formed. Following the hospital’s guidelines, all the elective breast can
cer surgeries were performed after having negative SARS-CoV-2 test
done within 72 h pre-operatively. Patients who were found positive
during this test, their surgery was re-scheduled as soon as the COVID-19
RT-PCR test came out negative after 14 days (Fig. 1).
Data analysis was carried out by making use of SPSS Statistics 26
(IBM Corporation, Armonk, NY, USA). The categorical data were re
ported as frequencies and percentages while continuous variables were
described as mean/median and interquartile range (IQR). To evaluate
the differences between the Pre-COVID-19 and COVID-19 cohorts, a Chisquare/Fisher’s exact test was employed for categorical variables and an
independent-t-test/Mann Whitney test was utilized for continuous var
iables using a p-value of less than 0.05 as statistically significant.

2. Materials and Methods
A retrospective comparative cohort study was performed in the
Section of Breast Surgery at tertiary care cancer unit. Ethical approval
was granted by the Institution’s Research Ethics Committee (reference
number: 2020-5418-14043) before the initiation of the research project
and was carried out according to the principles of the Helsinki Decla
ration [13]. Informed consent is not required due to the observational
nature of the research. The study has been registered with German
Clinical Trials Register (DRKS) (Registration ID: DRKS00026114, https
://www.drks.de/drks_web/navigate.do?navigationId=trial.
HTML&TRIAL_ID=DRKS00026114) and fulfilled the reporting guide
lines of STROCSS criteria [14].
A total of 800 medical record files were reviewed including all breast
cases who registered for the first time in hospital having Breast cancer,
survivors, patients receiving systemic treatment for Stage IV disease and
visited breast clinic for follow up/response assessment or evaluation for
screen detected abnormalities, benign breast conditions or lumps or
visited breast clinic for second opinion from March 1, 2019 to 31rst
March 2021. We found that during the pre-pandemic period i.e. from 1st
March 2019 to 14th March 2020, 231 patients had surgeries for breast
cancer, 101 had procedures either for benign conditions or had diag
nostic image guided surgeries, 25 found to have Stage IV disease, 12
patients who were booked for surgery were lost to follow-up and 144
patients cancer survivors visited clinic. Thus, a total of 513 patient files
were assessed. On the other hand, during the pandemic period (15th
March 2020-31rst March 2021), 149 patients were operated for proven
breast cancer, 35 patients were having benign breast disease, 18 were
Stage IV patients, 35 patients were booked for surgery but lost to followup (Declined surgery as contacted through Hotline service because of
COVID Situation) and 50 were breast cancer survivors. Thus, 287
medical records were assessed during the second time-period.
For comparative analysis, Breast cancer patients were stratified into
two cohorts (Group A and Group B). Group A comprised of all patients
who underwent surgery for proven breast cancer before the onset of
COVID-19 pandemic i.e. between 1st March 2019 and 14th March 2020
while Group B included all those patients who were operated between
15th March 2020 and 31rst March 2021, this time period coincides with
the COVID-19 outbreak era. Those patients were not accrued in the
study whose medical records were either incomplete or lost to follow-up
or receiving primary systemic treatment for their metastatic disease.

3. Results
After reviewing 800 electronic medical records of breast cancer pa
tients, a total of 380 subjects who underwent surgery in the above
mentioned time period met the inclusion criteria of the present study. Of
these 231 (60.79%) were operated in pre-pandemic period and thus
were included in Group A while 149 (39.21%) patients had their surgery
done in pandemic period and accrued in Group B (overall 35.5% decline
in breast cancer surgeries) (Fig. 2). A total of 3252 patients visited the
hospital during the pre-pandemic period. This value had been reduced to
2028 patients during the pandemic period. Thus, a decrease of 32.4%
has been recorded in patients visiting the hospital.
As evident from Table 1, data analysis revealed statistically signifi
cant differences in the baseline characteristics of two study cohorts
except for the mean age at diagnosis of (p = 0.885). Most of the patients
were diagnosed with Invasive Ductal Carcinoma (IDC) upon histological
examination representing 80.1% of cases in Group A and 77.9% of cases
in Group B (p < 0.001). Relatively, Grade 2 disease was noticed in large
proportion of study population of Group A than in patients of Group B
[124 (53.8%) vs. 76 (51.0%), p < 0.004]. In Group A, half of the patients
143 (61.9%) were observed with Luminal Type as compared to Group B
where substantial number of study subjects 104 (74.8%) were charac
terized with this molecular subtype respectively (p < 0.002). Approxi
mately a great majority of cases 112 (48.5%) presented with stage II
breast cancer in group A whereas in Group B, it contributed to 65
(43.6%) cases (p = 0.023). Neoadjuvant chemotherapy was adminis
tered to half of the patients 119 (51.5%) in Group A and 69 (46.3%)
patients of Group B (p = 0.032).
Table 2 outlines the types of surgical intervention performed and
management outcomes of the study population which demonstrated no
major difference in the waiting time for surgery between Group A and
Group B patients (p = 0.487) except for those patients who tested pos
itive on pre-operative COVID-19 RT-PCR test 12/149 (8.05%).
2
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Fig. 1. COVID testing algorithm for surgery patients.

out in Group A than in Group B (7.8% vs. 2.7%, p < 0.013). A decline in
sentinel lymph node biopsy was recorded during COVID-19 pandemic
[157 (67.9%) vs. 108 (72.5%), p < 0.013]. Post-operative hospital stay
was minimised in patients of Group B in order to reduce nosocomial
spread of COVID-19 virus (1.4 days vs. less than one day, p < 0.001).
Despite it, one patient contracted the virus during its postoperative stay
and expired [1/149 (0.67%)]. She was an ASA class 3 a 69 year old
woman with multiple comorbid illnesses including hypertension, dia
betes and severe COPD, operated under local anaesthesia for a breast
conserving procedure.
The number of postoperative complications were consistent between
the two time periods (mean 4.0, p < 0.001) which included haematoma,
seroma formation, wound infection and flap necrosis. All of these pa
tients were managed as outpatients and none of them required readmission in hospital. In addition, no major change in the waiting
time for postoperative oncological consultation was detected between
the two study groups (mean 2.0 days, p < 0.001). Waiting time for
adjuvant chemotherapy (mean 7.0 days, p = 0.484) as well as waiting
time for radiotherapy (mean 7.0 days, p = 0.484) did not differ between
Group A and Group B.

Fig. 2. Operative volume trend during COVID-19 pandemic.

Therefore their surgeries were performed between 14 days and 35 days
as per WHO guidelines once they turned negative for COVID-19 virus.
Fortunately, all of these infected patients were asymptomatic, isolated at
home and were continuously monitored by the telehealth facilities of the
hospital which connected them to their primary consultant and infec
tious disease specialist. In early 6 weeks of pandemic, only 10 cancer
surgeries were performed while 04 patients who were hormone receptor
positive scheduled for surgeries were cancelled and started on hormonal
treatment to delay surgical intervention for at least 8 weeks giving a
cancellation rate of 28.6%. Study results also identified that a large
number of patients in the study were subjected to breast mastectomy
which consisted of 154 (66.7%) cases in Group A and 104 (69.8%) cases
in Group B. Likewise, more breast reconstruction surgeries were carried

4. Discussion
This is the first study reporting impact of SARS-CoV-2 virus on sur
gical care of breast cancer patients during this pandemic era overall
from a lower middle-income country. This virus has remained inciting
panic for Pakistan, being a lower middle-income country (LMIC) with
limited health care budget and fragile health care system. Not only were
there challenges due to the pandemic but also the health care system had
to deal the myths and false beliefs associated with COVID-19 country
wide which contribute to a negative impact on the outcome [12]. Our
3
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Table 1
Demographic and clinicopathological data of breast cancer patients.

Table 2
Surgical and management outcomes of breast cancer patients.

Variable

Total n =
380

Group A (01/3/
2019–14/3/
2020) n = 231
(60.79%)

Group B (15/3/
2020–31/3/
2021) n = 149
(39.21%)

p-value

Variable

Total
n=
380

Group A (01/3/
2019–14/3/
2020) n = 231
(60.79%)

Group B (15/3/
2020–31/3/
2021) n = 149
(39.21%)

p-value

Age in years

380

6 (4.0%)
58 (38.9%)
0 (0%)

4.4 (IQR,
4.0–4.5 days)
–

4.4 (IQR,
4.0–4.5 days)
Positive
12 (8.05%)

0.487

33 (14.3%)
52 (22.5%)
01 (0.4%)

230
380

145 (62.8%)

85 (57.1%)

301

185 (80.1%)

116 (77.9%)

24

14 (6.1%)

10 (6.7%)

22

16 (6.9%)

6 (4.0%)

77 (33.3%)
154 (66.7%)
18 (7.8%)
157 (67.9%)
1.4 (IQR,
1.0–1.5 days)
4.0 (IQR,
4.0–5.0)
2.0 (IQR,
2.0–3.0 days)

45 (30.2%)
104 (69.8%)
4 (2.7%)
108 (72.5%)
Less than one
day
4.0 (IQR,
3.0–4.0)
2.0 (IQR,
2.0–3.0 days)

13

8 (3.5%)

5 (3.4%)

12

6 (2.6%)

6 (4.0%)

8
380
26
200
154
370
(missing n
= 10)
247
76
47
380

2 (0.8%)

6 (4.0%)

Waiting time for
surgery
Pre-operative
COVID-19 test
Result (n = 149)
Surgical Intervention
BCS
Mastectomy
Reconstruction
SLNB
Post-operative
Hospital Stay
Post-operative
complications
Waiting time for
postoperative
oncological
consultation
Waiting time for
chemotherapy
Waiting time for
radiotherapy

380

380
39
110
01

51 (IQR, 27–76
years)

0.885

Comorbidities
Diabetes
Hypertension
Valvular Heart
Disease
None
Tumour
Pathology
Invasive Ductal
Carcinoma
Invasive Lobular
Carcinoma
Ductal
Carcinoma in
Situ
Metaplastic
Carcinoma
Papillary
Carcinoma
Others
Tumour Grade
Grade 1
Grade 2
Grade 3
Molecular
Subtype

51 (IQR, 22–78
years)

7.0 (IQR,
7.0–8.0 days)
7.0 (IQR,
7.0–8.0 days)

7.0 (IQR,
7.0–8.0 days)
7.0 (IQR,
7.0–8.0 days)

11 (4.7%)
124 (53.8%)
96 (41.5%)

15 (10.1%)
76 (51.0%)
58 (38.9%)

143 (61.9%)
50 (21.64%)
38 (16.45%)

104 (74.8%)
26 (18.7%)
9 (6.5%)

63
77
177
63
380

36 (15.6%)
45 (19.5%)
112 (48.5%)
38 (16.4%)

27
32
65
25

188
192

119 (51.5%)
112 (48.5%)

69 (46.3%)
80 (53.7%)

Luminal Type
Triple Negative
Her 2 enriched
Tumour Stage
(Pathological)
Stage 0
Stage I
Stage II
Stage III
Neoadjuvant
Chemotherapy
Yes
No

<0.001

<0.001

380
122
258
22
265
380
380
380

380
380

–

<0.013

<0.001
<0.001
<0.001

0.484
0.484

<0.004

provide essential care with safety for all. The term elective for cancer
cases was revisited understanding the fact that delay could have impact
on stage progression and psychological well-being and quality of life of
patients hence cancer lists were prioritized. A total 52 cases were
operated in May–July 2020 period which was nearly equivalent to preCOVID-19 era. During this period Breast conservation vs mastectomy
remained the same as compared to pre-COVID-19 period. Subsequently
from August 2020 till May 2021, infectivity rate had passed through
second and third waves with sharp rise to a steep decline but fortunately
each wave had less powerful impact as compared to other LMICs like
India, despite it we found that number of cancer surgeries had dropped
to 106 as compared to 131 in pre-COVID-19 era at our institution.
Worldwide data from different cancer centers had reported several
reasons for decline in cancer surgeries and less efficient cancer care
during first peak i.e., March to May 2020 [16,17]. A multicenter study
from Netherland associated this decline to reduce referrals from Na
tional screening programs and General practitioner practices with drop
in T1-T2No cases [17].
During first wave none of the patients were offered reconstructions
as per guidelines to reduce operating room time, post-operative hospital
stay and to avoid reconstruction associated issues with anticipated
several clinic visits if they developed any post-reconstruction compli
cation which could be associated with increased risk of hospital acquired
COVID-19 infection. A study from Italy showed reduced surgical pro
cedures during pandemic with marked decrease in reconstructive pro
cedures similar to our study results (p < 0.001) [16]. This is in line with
recommendations from ESMO to keep breast reconstructions as low
priority [11]. Contrary to that from August 2019 to May 2020 the rate of
reconstructions had increased at our institution, all these patients had
relatively smooth post-operative course with no major reconstruction
related complications like infection, wound dehiscence or reconstruc
tion failure and numbers were comparable to figures performed in same
period in 2019.
As far as waiting time for surgery is concerned there was no differ
ence between pre-COVID-19 and COVID-19 eras. Sentinel node biopsy
was offered as per routine as institution was having an enough supply of
Nano colloid available. Likewise, previously cited study conducted in
Italian Breast Unit also reported no change in use of sentinel lymph node
biopsy before and during COVID-19 pandemic (p = 0.84) however they
reported that patients who were on the operating lists during the COVID-

<0.002

(18.1%)
(21.5%)
(43.6%)
(16.8%)

–

0.023

0.032

study showed that the overall number of breast cancer surgeries had
declined when comparing to Pre-COVID-19 era with compromised
cancer care.
During this exceptional situation to avoid delays in surgical care of
breast cancer patients, multi-disciplinary teams including breast sur
geons have been working continuously to modify the management of
breast cancer patients, guidelines have been formulated and followed to
avoid unforeseen complications among breast cancer patients [12].
The first wave of COVID-19 occurred from March to July 2020 hence
based on institutional guidelines, cancer surgery was offered to a limited
group of breast cancer cases; it was a time when the COVID -19 infec
tivity rate was high (279,146 reported cases) with an ongoing under
standing about transmission, control, treatment, and impact on
immunocompromised cancer patients [7]. In first 6 weeks, only 10
cancer surgeries were performed with a reduced level of care for breast
cancer patients. 04 patients who were hormone receptor positive
scheduled for surgeries in early 6 weeks were cancelled and started on
hormonal treatment to delay procedures for at least 8 weeks (cancella
tion rate of 28.6%), it was a time when COVID Surg Collaborative also
anticipated that cancellation rate would be 37.7% for cancer surgeries
during peak 12 weeks of outbreak [15].
Subsequently hospital had developed a policy of having mandatory
negative COVID-19 RT-PCR test within 72 h of proposed surgical date to
4
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19 pandemic had to wait slightly longer for their surgical intervention
than the patients scheduled for their surgery before the COVID-19
pandemic (49.11 vs. 46.39 days) [16]. On the contrary, study from
Canadian cancer center showed no major difference in surgical care as
compared to Pre-COVID-19 era with improved waiting time which they
associated with low impact of COVID-19 in their center and to better
team based care [18].
During the pandemic time hospital had made policy to discharge
stable patients as early as possible hence post-operative hospital stay
was reduced in this era to reduce exposure and simultaneously to reduce
workload to health care providers, patients were connected to team
members via teleconsultations to monitor their health condition and to
address wound related issues. Anecdotal evidence proved that patients
were also satisfied as it reduced hospital encounters which is evidently a
high transmission pocket [19].
In comparison to developed countries, Pakistan does not have any
National Cancer Screening Program nor having a stringent General
practitioner practice system, our workload is based on cases who pre
sented with self -discovered lumps or diagnosed with breast cancer at
other hospitals, only <2% of cases at our center treated after being
picked on Screening. We found that fears associated with COVID-19 was
the strongest reason for decline in elective cancer surgeries at our center,
there were diagnosed cancer cases who deliberately missed their clinic
and surgery appointments for several months and presented afterward
with upgrade stage during this era. We also found a fear to get treatment
in a hospital such as ours which offers COVID-19 related care in a
designated area entirely separated from the main hospital, this was also
the strongest reason to delay treatment. Many patients who were con
tacted through telecommunication sought alternative therapies like
spiritual healing, herbal, or homeopathic treatment as they were waiting
for pandemic to over before they sought proper cancer treatment. Pro
spectively collected data showed that rate of stage III disease at pre
sentation has increased up to 38% (25–30% in pre-COVID-19 era) and
stage IV by 14% as compared to our institutional figure of 7–10% every
year since 2010. Pakistan has been experiencing a 4th wave currently
with almost 100% infective cases of the Delta variant in Karachi, hoping
to curb disease successfully without conceding further care.
There were certain limitations to our study, the first being a single
center experience from a private sector and the other having a small
sample size, however to the best of our knowledge this study is one of the
few studies showing the impact of COVID-19 on surgical care of cancer
patients from lower- and middle-income countries (LMICs). Further
research should be conducted in this regard including all the public and
private sector institutions to better understand the impact of prevailing
pandemic on breast cancer surgery and to enhance understanding for
unforeseen other future pandemics.
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COVID-19 pandemic has had reverberations on the breast surgery
oncologic practice at our institution with marked decline in number of
surgical interventions despite of timely planning and strategizing breast
cancer management. This likely resulted from fear among community
and cancer patients to acquire COVID-19 infection from hospital terri
tories leading to lesser cancer diagnosis and treatment. Later on, patients
presented with an advanced cancer stage demanding more aggressive
treatment. Therefore, the findings of our study warrant strengthening of
current breast cancer management policies and stringent infection
control measures to provide uninterrupted standardized cancer care in
the ensuing and future pandemics.
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